Lysyl oxidase like-2 (LOXL2) is known to drive fibrogenesis and is also believed to be involved in the progression of PSC and non-alcoholic steatohepatitis (NASH). This evidence concerns the gene LOXL2 and metabolic dysfunction-associated steatohepatitis.